Journals / MN Oftalmoloji / 2014 / Cilt: 21 - Sayı: 2

The effect of ıntravitreal ınjection of ranibizumab on the progression of stage 1 posterior vitreous detachment

İntravitreal ranibizumab enjeksiyonunun evre arka vitreus dekolmanında ilerlemeye etkisi

Pages
114–118
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PVD must be evaluated and followed because of it may change the effect of the drug and response to the treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Investigate the incidence and progression of stage 1 posterior vitreus detachtment (PVD) in patients with exudative age-related macula degeneration following intravitreal in- jection of ranibizumab.
📊
Key Findings & Data:The patients with stage 1 PVD were analyzed in detail before and after injections.
💡
Conclusion & Impact:PVD must be evaluated and followed because of it may change the effect of the drug and response to the treatment
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Investigate the incidence and progression of stage 1 posterior vitreus detachtment (PVD) in patients with exudative age-related macula degeneration following intravitreal in- jection of ranibizumab. Material and Method: In this retrospective study, the images of the spectral optical coher- ence tomography was evaluated in patients with exudative age-related macular degeneration following intravitreal ranibizumab injection. The patients with stage 1 PVD were analyzed in detail before and after injections. Patients who progressed to stage 2, stage 3, stage 4 was recorded with using the images of optical coherence tomography. The statistical studies were performed with using Wilcoxon signed rank test, Mann-Whitney U Test, Correlation analysis and Fisher’s exact chi-square test. Results: 39 eyes of 39 patients with stage 1 PVD were included. Patients' ages ranged from 48 to 87, mean age was 69.6 ± 9.4 years. In 8 (20.5%) patients progression were detected. The average age of these patients was found to be 76.3 ± 8:34 year. The average number of injection was 2.2 and follow up time was 9.1 weeks. Positive correlation was detected between increasing age and progression of PVD. Conclusion: Intravitreal injection of ranibizumab may lead to progressing of stages of PVD especially in elderly patients. PVD must be evaluated and followed because of it may change the effect of the drug and response to the treatment

Özet

Amaç: Optik Koherens Tomografisi ile evre 1 arka vitreus dekolmanı (AVD) tespit edilen eksudatif yaşa bağlı maküla dejenerasyonu hastalarında intravitreal ranibizumab enjeksiyonu sonrası AVD evresinde ilerlemeyi ve sıklığını araştırmak. Gereç ve Yöntem: Bu retrospektif çalışmada, eksüdatif yaşa bağlı maküla dejenerasyonu tanısı alan ve intravitreal ranibizumab enjeksiyonu yapılan hastaların, Spektral-domain optik koherans tomografisi görüntüleri değerlendirildi. Evre 1 AVD tespit edilen hastaların enjeksi- yon öncesi ve sonrası dönemdeki bulguları detaylı olarak incelendi. Optik koherans tomogra- fisi görüntülerine bakılarak evre 2, evre 3 ve evre 4 AVD’ye ilerleyen hastalar tespit edildi. İstatistiksel çalışmalar Wilcoxon ilişkili iki örneklem testi, Mann-Whitney U Testi, Korelasyon analizi ve Fisher kesin ki-kare testi kullanılarak yapıldı. Bulgular: Evre 1 AVD tespit edilen 39 hastanın 39 gözü çalışmaya alındı. Hastaların yaş- ları 48 ile 87 arasında değişmekte olup, yaş ortalaması 69,6±9,4 yıl olarak tespit edildi. Toplam 8 (%20,5) hastada ilerleme saptandı. Bu hastaların yaş ortalaması 76,3±8,34 yıl ola- rak tespit edildi. Ortalama enjeksiyon sayısı 2,2, ortama takip süresi 9,1 hafta idi. Yaş ile AVD evresinde ilerleme arasında pozitif korelasyon saptandı. Sonuç: İntravitreal Retina (İR) enjeksiyonu, özellikle ileri yaş hastalarda hastalarda, AVD evresinde ilerlemeye neden olabilmektedir. AVD’ de ilerleme, verilen ilacın tedaviye cevabını etkileyebileceği için mutlaka değerlendirilmeli ve takip edilmelidir.

🔖

Cite This Article

GÖKTAŞ, S., SAKARYA, Y., ÖZÇİMEN, M., SAKARYA, R. (2014). The effect of ıntravitreal ınjection of ranibizumab on the progression of stage 1 posterior vitreous detachment. MN Oftalmoloji, Cilt: 21 - Sayı: 2, 114–118. https://ajindex.com/articles/295679

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Aslankara H, Öner FH, Yaman A, Ergin MH, Saatci AO.Yaş Tip Yaşa Bağlı Maküla Dejenerasyonunda İntravitreal Rani- bizumab Enjeksiyonu. Ret-Vit 2010;18:134-8
  2. Karaca U, Durukan AH, Erduman FC, Sobacı G, Bayraktar MZ. Yaş Tip Yaşa Bağlı Makula Dejenerasyonunda İntravit- real Ranibizumab Tedavi Sonuçlarımız. Turk J Ophthalmol 2012;42:25-9. 3.Morita H, Funata M, Tokoro T. A clinical study of the develop- ment of posterior vitreous detachment in high myopia. Retina 1995;15:117-24. 4.Chuo JY, Lee TY, Hollands H, et al. Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 2006;142:931-7
  3. Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 2005;103:537-67
  4. Jackson TL, Nicod E, Angelis A, et al. Vitreous Attachment in Age-Related Macular Degeneration, Diabetic Macular Edema, And Retinal Vein Occlusion. Retina 2013;33:1099- 108
  5. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothe- lial growth factor therapy in Medicare patients with age-re- lated macular degeneration. Am J Ophthalmol 2011;152: 266–72 8. Simpson A, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration-a review. Surv Opthalmol 2012;57:498-509
  6. Stalmans P, Delaey C, De Smet MD, Van Dijkman E, Pakola S. Intravitreal İnjection Of Microplasmin For Treatment Of Vitreomacular Adhesion: Results Of A Prospective, Randomized, Sham-Controlled Phase II Trial (The MIVI-IIT Trial). Retina 2010;30:1122-7
  7. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Grae- fes Arch Clin Exp Ophthalmol 2007;245:576-80
  8. Quiram PA, Leverenz VR, Baker RM, et al. Microplasminin- duced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-6
  9. Stefansson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-63
  10. Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H. Posterior vitreous detachment following intravitreal drug in- jection. Graefes Arch Clin Exp Ophthalmol 2013;251:1691-5
  11. Hoehn F, Mirshahi A, Hattenbach LO.Optical coherence to- mography for diagnosis of posterior vitreous detachment at the macular region. Eur J Ophthalmol 2009;19:442-7
  12. Uchino E, Uemura A, Ohba N. Initial stages of posterior vitre- ous detachment in healthy eyes of older persons evaluated by optical coherence tomo